Editorial - Journal of Experimental Stroke & Translational Medicine (2023) Volume 15, Issue 1

organisations who conduct request for proposals in translational medicine

Shuji Kitajima*

The European Society for Translational Medicine (EUSTM), Vienna, Ethiopia

*Corresponding Author:
Shuji Kitajima
The European Society for Translational Medicine (EUSTM), Vienna, Ethiopia
E-mail: shuji@edu.com
Received: 04-Jan-2023, Manuscript No. JESTM-23-85721; Editor assigned: 06-Jan-2023, PreQC No. JESTM-23-85721 (PQ); Reviewed: 20- Jan-2023, QC No. JESTM-23-85721; Revised: 24-Jan-2023, Manuscript No. JESTM-23-85721 (R); Published: 31-Jan-2023, DOI: 10.37532/ jestm.2023.15(1).12-14


The paradigm of medical research is changing from compound-based to evidence-based drug/device discovery as a result of transitional medicine/science. It is promoting the use of cutting-edge technologies, fostering interdisciplinary collaborations, and accelerating the delivery of treatments to patients. Applying what is learned from preclinical trials and bringing the ensuing safety and efficacy to clinics is the central tenet of evidence-based discovery. A contract research organisation (CRO) performs activities for a sponsor in the medical disciplines like a hired agent with the necessary training and expertise. The contract is for deliverables and the relationship is business-related. This for-profit industry has developed in the last ten years due to the rising number of sponsored outsourced work. Geographical boundaries are becoming more hazy as a result of cross-border regulatory evaluations and scientific globalisation. The path from bench to bedside is lengthy, filled with challenges and tall hurdles. For ideas to come to life and be commercialised, effective teamwork becomes crucial. Drug/device manufacturers and CROs are among the professionals in team communities.


Collaboration CROs • EBIS • Paradigm shift • Translational medicine


With the development of products through in vitro, in vivo, and ex vivo testing during preclinical research and clinical trials, CROs’ critical roles in the chain of discovery and design are becoming more and more clear. The collaborative nurturing of materialisation and increasing of pipeline productivity are under the purview of project management teams. [1] No one organisation is fully capable of providing integrated services, with knowledge of every link in the chain, to meet the needs of a variety of sponsors because CROs have many functional characteristics and specialties. Instead of the few huge CROs competing with one another, Expertise-Based Integrated Services allow allied CROs to share the always growing market demands. Empirically, the information derived from the selected The regulatory conditions for approval should be satisfied by CROs. Prior to contracting, a quality assurance unit from the sponsor should be cautious in conducting audits and inspections of the prospective CROs. Therefore, careful observation and well-coordinated project management guard the way to the submission of the applications successfully. An effective and timely connection between clinical research organisations (CROs) and patient populations is ensured through a strategic relationship between translational medicine and CROs. [2] Drug research and device control design can be patient-driven using the unbiased data produced by CROs’ services. Findings from the combined efforts can then be used to close the feedback loop and advance the development of both new and improved pharmaceuticals. A dating service could develop and grow from [3].


After invention, the road to a marketed drug or device is lengthy, twisting, and perilous, requiring enormous financial and intellectual commitments. However, putting a lot of time and effort into this course does not ensure that a successful application will be approved by regulatory bodies because there is a chance that obstacles will appear at every turn. Bioinformatics has been produced in vast quantities as a result of extensive study into chemical libraries and the precise production of proteins to find medications.

Over the past 20 years, significantly better biocompatibility has been made possible by the development of new, refined synthetic biomaterials for the manufacture of implanted devices. [4] The distinction between biologics and devices has become less distinct, and their interdependence has grown, as a result of innovations like drug-eluting stents and nanotechnology in formulation. requests from Because of concerns about safety, accessibility, and cost, regulatory assessments, clinical settings, and health care operations have pushed for disclosure of the mechanisms of action of medications. Additionally, the ability to create value is crucial for inventors to persuade financiers to continue providing financial support, which logically reflects the crucial approaches of selecting research and development (R&D) methods and establishing commercial milestones. Given these conditions, translational medicine manifests the developed evidence-based medicine.

Value and productivity are tightly related. [5] The goal of mergers and acquisitions (M&As) in the medical sector is to increase productivity and ultimately achieve top-line growth [10]. Ironically, research has found that industry consolidation leads to lower R&D spending. It is clear as day that R&D results, whether When new drug approvals are considered, the investment is significantly decreased. Due to the lengthy time required to produce compelling results and the change in financial support to clinical trials, early-stage R&D is most negatively impacted. The attrition of human resources has caused M&As to significantly disrupt the continuity of scientific research and organisational stability. During personnel changes, small but important pieces of know-how may be lost. To move items through the pipelines, the remaining workers may encounter significant project management challenges. In these conditions, outsourcing replaces the inefficient cross-functional consortiums formed within each company and among the affiliated enterprises as the preeminent way to preserve productivity. groups that conduct paid research [6]

Contract research organisations (CROs) for pharmaceuticals were utility corporations performing high volume throughputs, organising clinical trials, and performing toxicological assessments before and in the early phases of the computer era. They have developed to meet the more complex demands of the understaffed pharmaceutical and medical device industries, which include carrying out tests to determine the pharmacokinetics, pharmacodynamics, and/or biocompatibility of implants under physiologically normal conditions, as well as pharmacological efficacy and/or tissue engineering repairs in specific disease models. Preclinical and clinical research are on different continents in CROs. [7] Toxicology/biocompatibility, compound synthesis/device manufacture, efficacy/ functional repair, and drug screening/ design control are the major subgroups of the former. To comply with regulatory regulations, the latter conducts operations through a series of steps in human studies. The distinctions that previously separated corporations from brands have become more hazy as a result of mergers and acquisitions (M&As) and generic medicines, despite the pharmaceutical industries’ preference to hang onto intellectual property. Executives in the medical sector have discovered that collaborations with competitors who share their goals could result in a quicker return on their R&D investments. It is common knowledge that objective statistics should be produced by a neutral third party to persuade business partners and regulatory organisations. The favourable environment for CROs is consequently still present.[8]

expand and has actively engaged in medical sciences at every stage, from concept to commercialization.

Working together, sponsors and CROs [9]

There are a few typical business structures for agreements between a sponsor and a CRO. The majority of contracts are still traditional project-based agreements, but partnership Full Time Employee (FTE)-based agreements have recently started to gain ground. Strategic partnerships with CROs help teams tackle problems from a variety of corporate cultures and operational pillars by fostering trust and facilitating more regular, open communication on project specifics and priorities. [10]

Selecting a CRO criteria

Sponsors looking for a dependable CRO to handle outsourcing work evaluate candidates based on their technical proficiency, quality, turnaround time, and cost. The achievement of product development objectives is made possible by technical competency, which is the capacity to carry out and expertise in carrying out related tasks. In the age of biosimilars and 510(k) products, familiarity with the targeted commercial product dramatically decreases the learning curve, eliminates guesswork, and prevents needless failures. A number of other challenges will be overcome with the aid of prior experience with similar studies. The two unified fundamentals for regulatory filings are quality control and assurance. They not only outline best practises for all types of activities, but they also help to establish the reliability of the data that has been collected. Performance in these areas that meets expectations is promised.

A speedier and more efficient regulatory review procedure. The data gathering milestones for product development depend on carefully controlled project timeframes, which reduce overall costs. Gantt charts that are aggressively prepared frequently result in widespread stress and human mistake. During complicated processes, consensus logistics management can set expectations and manage them. Shortcuts and seemingly straight routes frequently result in higher repair costs and/or a higher chance of failure due to hurry. Commoditizing on contract rates is a quality killer because it may take more time and money to undo a failed attempt. It goes without saying that this has a significant impact on how quickly product development is moving forward.

Making the connection

The ideal situation would be for integrated services to be provided by a single CRO, which is practically a replica of the pre-existing atmosphere and operational methods in the inventor’s facilities prior to restructuring. It goes without saying that this ideal situation has the same traps as the outdated systems. The best employees in particular service areas may be easier to find at larger CROs, but the layers of communication can impede the efficient flow of discovery and design in product development. The development of a scientist into a project manager at the inventor’s facilities should emphasise talent, intuition, drive, and leadership. This difficult assignment is comparable to choosing a field marshal to lead from among rated generals. choosing numerous CROs instead, each with their own pros and cons s own narrowly concentrated specialties, could be a great substitute. That is, a person with excellent scientific intuition and extensive interpersonal communication abilities can organise programmes into a stream and make each CRO’s study/technical director the field marshal of a particular segment while bringing the idea to market.


  1. Jazeel. Singularity A manifesto for incomparable geographies. Singap J Trop Geogr. 40, 5-21 (2019).
  2. Indexed at, Google Scholar, Crossref

  3. Whitham Ben. Post-crash neoliberalism In theory and practice. Political Stud Rev.16, 252-264 (2018).
  4. Indexed at, Google Scholar, Crossref

  5. Chakrabarty, Dipesh. Subaltern studies and postcolonial historiography. Nepantla. 1, 9-32 (2000).
  6. Indexed at, Google Scholar, Crossref

  7. De Boeck. Divining the city: rhythm, amalgamation and knotting as forms of urbanity. Soc Dyn. 41, 47-58 (2015).
  8. Indexed at, Google Scholar, Crossref

  9. Filip. The Tower. A Concrete Utopia. Notes on a video-installation by Sammy Baloji and Filip De Boeck (2015). 84-88 (2015).
  10. Indexed at, Google Scholar

  11. Geenen, Kristien. Sleep occupies no space: The use of public space by street gangs in Kinshasa. J Relig Afr. 79, 347-368(2009).
  12. Indexed at, Google Scholar, Crossref

  13. H Stevens, Jeroen. Urban porosity: a chronicle of spatial inclusion in Matonge, Brussels. J Urban.15, 61-83(2022).
  14. Indexed at, Google Scholar, Crossref

  15. Beneduce, Roberto. The moral economy of lying: Subjectcraft, narrative capital, and uncertainty in the politics of asylum. Med Anthropol. 34, 551-571 (2015).
  16. Indexed at, Google Scholar, Crossref

  17. Pype, Katrien. Confession cum deliverance: In/Dividuality of the subject among Kinshasa’s born-again Christians. J Relig Afr. 41, 280-310 (2015).
  18. Indexed at, Google Scholar, Crossref

  19. Geenen Kristien. Pedestrian Itineraries in Kinshasa: On Shortcuts, Permeable Walls, and Welded Shut Gates in a Former Colonial Hospital. Space Cult. 24, 113-127 (2021).
  20. Indexed at, Google Scholar, Crossref